This section contains information intended for healthcare professionals only. From this section, you can access the full healthcare professional website, the eSlide library for ENABLEX® (darifenacin) speakers, and printable vouchers for your patients.

 
 

Welcome Healthcare Professionals

Prescribe ENABLEX for the Control of
Your Overactive Bladder (OAB) Patients

Patients Get Drier Fast

  • ENABLEX reduced wetting accidents by up to 52% at 2 weeks1*

 

Works Across Patient Types†

  • Proven to reduce wetting accidents, even in severely incontinent patients2

Patients Stay Dry Long-Term

  • Up to 76% reduction in wetting accidents at 3 months3‡
  • Confidence that comes with the only published 2-year OAB study4

Graph

Results from a multicenter, open-label, 2-year extension study that enrolled 716 patients from two 12-week double-blind feeder studies (n=600 at 3 months, n=543 at 6 months, n=497 at 12 months, and n=466 at 24 months). Total number of older patients (≥65 years): 199 at baseline, 173 at 3 months, 156 at 6 months, 140 at 12 months, and 135 at 24 months.

*
25% median reduction from baseline in the placebo group (P=0.003 and P<0.001 for ENABLEX 7.5 mg and 15 mg vs placebo).
†
Patient types: mild-to-moderate incontinence defined as <21 episodes per week and severe incontinence defined as ≥21 episodes per week.2
‡
Pooled results from 3 fixed-dose clinical trials. Placebo rates: up to 35% versus ENABLEX 7.5 mg and 45% versus ENABLEX 15 mg in older patients. P<0.001 versus placebo.



See Full Prescribing Information.

References:

1. Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol. 2004;45:420-429.

2. Data on file (NDA, severity data, Hill, business data). Novartis Pharmaceuticals Corporation.

3. Foote J, Glavind K, Kralidis G, Wyndaele JJ. Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist. Eur Urol. 2005;48:471-477.

4. Haab F, Corcos J, Siami P, et al. Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study. BJU Int. 2006;98(5):1025-1032.

MedScape® from WebMD

This section covers the efficacy, tolerability, safety, dosing flexibility, and mechanism of action of ENABLEX. Enter MedScape

eSlide Library

The eSlide Library provides approved slides and other materials to trained speakers for ENABLEX. Password required. Enter eSlide Library

Patient Vouchers

Download and print vouchers here for your patients to try ENABLEX for free. You may print 10 valid vouchers per visit to this site. You will need to provide your medical license number.

Print